Aimmune Therapeutics (NASDAQ:AIMT) was upgraded by BidaskClub from a “hold” rating to a “buy” rating in a report issued on Wednesday.

AIMT has been the topic of several other research reports. Cantor Fitzgerald reaffirmed a “buy” rating on shares of Aimmune Therapeutics in a research report on Tuesday, February 20th. Royal Bank of Canada began coverage on Aimmune Therapeutics in a research report on Wednesday, February 7th. They set an “outperform” rating and a $55.00 target price on the stock. Deutsche Bank set a $30.00 price objective on Aimmune Therapeutics and gave the stock a “buy” rating in a research report on Tuesday, February 20th. Piper Jaffray Companies began coverage on Aimmune Therapeutics in a research report on Friday, May 18th. They issued an “overweight” rating and a $30.01 price objective on the stock. Finally, Credit Suisse Group set a $45.00 price objective on Aimmune Therapeutics and gave the stock a “buy” rating in a research report on Tuesday, February 27th. One equities research analyst has rated the stock with a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Aimmune Therapeutics presently has an average rating of “Buy” and an average target price of $53.67.

Shares of Aimmune Therapeutics opened at $33.09 on Wednesday, Marketbeat Ratings reports. The company has a market cap of $1.88 billion, a P/E ratio of -12.68 and a beta of -0.36. Aimmune Therapeutics has a 12-month low of $15.97 and a 12-month high of $42.00.

Aimmune Therapeutics (NASDAQ:AIMT) last announced its earnings results on Tuesday, May 8th. The biotechnology company reported ($0.92) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.71) by ($0.21). During the same quarter in the prior year, the firm earned ($0.52) earnings per share. research analysts forecast that Aimmune Therapeutics will post -3.14 EPS for the current year.

In other Aimmune Therapeutics news, insider Douglas T. Sheehy sold 3,523 shares of the business’s stock in a transaction on Monday, March 5th. The stock was sold at an average price of $36.52, for a total value of $128,659.96. Following the transaction, the insider now owns 32,500 shares of the company’s stock, valued at $1,186,900. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Douglas T. Sheehy sold 3,296 shares of the business’s stock in a transaction on Tuesday, May 22nd. The stock was sold at an average price of $33.00, for a total value of $108,768.00. The disclosure for this sale can be found here. 24.56% of the stock is currently owned by insiders.

Several institutional investors and hedge funds have recently modified their holdings of the business. WINTON GROUP Ltd bought a new stake in shares of Aimmune Therapeutics in the first quarter valued at $262,000. Xact Kapitalforvaltning AB bought a new stake in shares of Aimmune Therapeutics in the first quarter valued at $207,000. Royal Bank of Canada raised its stake in shares of Aimmune Therapeutics by 4,412.4% in the first quarter. Royal Bank of Canada now owns 17,463 shares of the biotechnology company’s stock valued at $555,000 after buying an additional 17,076 shares during the period. Eventide Asset Management LLC raised its stake in shares of Aimmune Therapeutics by 27.6% in the first quarter. Eventide Asset Management LLC now owns 1,564,983 shares of the biotechnology company’s stock valued at $49,813,000 after buying an additional 338,983 shares during the period. Finally, Legal & General Group Plc raised its stake in shares of Aimmune Therapeutics by 55.2% in the first quarter. Legal & General Group Plc now owns 14,102 shares of the biotechnology company’s stock valued at $449,000 after buying an additional 5,015 shares during the period. Hedge funds and other institutional investors own 81.31% of the company’s stock.

Aimmune Therapeutics Company Profile

Aimmune Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy product candidate is AR101, an investigational biologic for the treatment of patients with peanut allergy.

Analyst Recommendations for Aimmune Therapeutics (NASDAQ:AIMT)

Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.